SOLICITATION NOTICE
B -- Recruit Breast Cancer Patients and Collect Clinical and Epidemiologic Data and Biospecimens
- Notice Date
- 1/3/2017
- Notice Type
- Presolicitation
- NAICS
- 541990
— All Other Professional, Scientific, and Technical Services
- Contracting Office
- Department of Health and Human Services, National Institutes of Health, National Cancer Institute, Office of Acquisitions, 9609 Medical Center Drive, Room 1E128, Rockville, Maryland, 20852, United States
- ZIP Code
- 20852
- Solicitation Number
- N02CP72511-24
- Archive Date
- 2/1/2017
- Point of Contact
- Kimesha Leake, Phone: 2402765669, Jolomi Omatete, Phone: 2402766561
- E-Mail Address
-
kimesha.leake@nih.gov, jolomi.omatete@nih.gov
(kimesha.leake@nih.gov, jolomi.omatete@nih.gov)
- Small Business Set-Aside
- N/A
- Description
- Contracting Office Address Department of Health and Human Services, National Institutes of Health, National Cancer Institute, Office of Acquisitions, 9609 Medical Center Drive, Room 1E226, Bethesda, MD 20892, UNITED STATES Description National Cancer Institute (NCI), Division of Cancer Epidemiology and Genetics (DCEG), Genetic Epidemiology Branch (GEB), plans to procure on a sole source basis services to continue the collection of fresh frozen breast tissues and formalin-fixed paraffin-embedded (FFPE) tissue slides in three hospitals from The Chinese Hospital of Hong Kong, 4/F School of Public Health, Prince of Wales Hospital, Shatin, N.T., Hong Kong SAR, China. This acquisition will be processed under FAR Part 12 - Acquisition for Commercial Items and will be made pursuant to the authority in FAR Part 13.106-1(b)(2) and 13.501-(a)(1) using simplified acquisition procedures for commercial acquisitions. The North American Industry Classification System code is 541990 and the business size standard is $15.0 Million. Only one award will be made as a result of this solicitation. This will be awarded as a firm fixed price type contract. The period of performance is estimated to be as follows: February 6, 2017 - February 5, 2018 It has been determined there are no opportunities to acquire green products or services for this procurement. The NCI is conducting a molecular epidemiology study by collecting normal and breast tumor tissues from breast cancer cases who are enrolled in an ongoing breast cancer case-control study (Night shift and breast cancer: a case-control study among Hong Kong women) led by The Chinese University in Hong Kong (CUHK). Eligible cases in the nightshift and breast cancer case-control study are identified from the Surgery or Oncology Departments of hospitals in Hong Kong. Each case is frequency-matched in five-year age groups to a hospital control who is randomly selected from the same hospital where the case comes from. All cases and controls are Chinese females, and all controls have no history of a physician-diagnosed cancer at any site. Approximately 1,000 incident female breast cancer cases and 1,000 age-matched controls have been recruited into the case-control study by the end of year 2013. Questionnaire data (including basic socio-demographic characteristics, lifetime habits of smoking and alcohol drinking, dietary habits and intake of supplements, anthropometric risk factors, reproductive factors, history of benign breast diseases, family cancer history of breast cancer, occupational and recreational physical activity, etc.) and blood are being collected from each participating subject. So far, the NCI has collected fresh frozen tissue from ~300 breast cancer cases. The overall goals of the NCI breast tissue study are: 1) to characterize molecular profile using detailed molecular profiling approaches and classify tumors into subtypes; 2) to examine the relationship between age onset and molecular/morphologic changes in normal breast tissues, tumor subtypes, breast cancer risk factors (including genetic and environmental), and clinical characteristics; and 3) to identify tumor subtype-specific risk factors using data in this study as well as data collected from other Asian studies. The specific aim for this procurement is to continue the collection of fresh frozen breast tissues and formalin-fixed paraffin-embedded (FFPE) tissue slides in three hospitals. The contractor shall: 1. Obtain written inform consent from study participants for tissue collection; 2. Collect fresh frozen breast tissues (two non-malignant and one tumor) and five 10um sections from FFPE blocks (two non-malignant and one tumor); 3. Store collected tissues properly (fresh frozen tissues in liquid nitrogen and FFPE tissue slides in tubes at room temperature) until the shipment to NCI; 4. Ship the tissue samples to NCI every 6 months; 5. Share clinical and epidemiologic data with NCI COR. Chinese University of Hong Kong (CUHK) is uniquely qualified to perform this work for the following reasons: 1) The goal of this study is to identify breast cancer subtypes in a unique Asian population. The work requires the collection of fresh frozen tissues which is unachievable in most hospitals due to the limited research capacity and excessive burden to the pathology lab. In addition, the NCI needs epidemiologic data for the NCI's research. CUHK is conducting a breast cancer case-control breast cancer study with a careful and comprehensive collection of clinical and risk factor data as well as blood for germline DNA from a large number of cases and controls. It would be the most efficient approach for the NCI to conduct a breast tissue study taking advantage of this existing resource and infrastructure; 2) Breast cancer patients will be recruited from CUHK-associated hospitals; no known commercial company has access to these patients. The NCI has previously successfully collected paired normal and tumor tissues from 300 invasive breast cancer cases. The NCI was able to obtain questionnaire data and clinical information for all these cases. Genomic DNA and total RNA extracted from these samples showed excellent quantity and quality, which demonstrates the high quality of the NCI tissue collection and storage process. This notice is not a request for competitive quotation. However, if any interested party, especially small businesses, believes it can meet the above requirement, it may submit a capability statement, proposal, or quotation, which shall be considered by the agency. The statement of capabilities and any other information furnished must be in writing and must contain material in sufficient detail to allow NCI to determine if the party can perform the requirement. Responses must be received in the contracting office by 11:00 AM EST, on January 17, 2017. All responses and questions can be emailed to Kimesha Leake, Contract Specialist via electronic mail at kimesha.leake@nih.gov. A determination by the Government not to compete this proposed requirement based upon responses to this notice is solely within the discretion of the Government. Information received will be considered solely for the purpose of determining whether to conduct a competitive procurement. In order to receive an award, contractors must be registered and have valid certification in the System for Award Management (SAM) through sam.gov. Reference: N02CP72511-24 on all correspondence.
- Web Link
-
FBO.gov Permalink
(https://www.fbo.gov/spg/HHS/NIH/RCB/N02CP72511-24/listing.html)
- Place of Performance
- Address: Department of Health and Human Services, National Institutes of Health, National Cancer Institute, Office of Acquisitions, 9609 Medical Center Drive, Room 1E226, Bethesda, MD 20892, UNITED STATES, United States
- Zip Code: 20892
- Zip Code: 20892
- Record
- SN04362180-W 20170105/170103234404-a5d8e9afac93a62349d530828b0d651c (fbodaily.com)
- Source
-
FedBizOpps Link to This Notice
(may not be valid after Archive Date)
| FSG Index | This Issue's Index | Today's FBO Daily Index Page |